Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Want to cut your energy bills? Here’s how five experts are doing it 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
NEW YORK, May 25, 2017 -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Kyle Sarwal and Ajit Johal to its Board of Directors.
Mr. Sarwal is a director and business development expert for SAJO Consulting, a company with management, research, scientific, and regulatory expertise. Mr. Sarwal has over 20 years’ experience in acquiring and growing companies, managing technology and information systems, managing teams and businesses, advisory and strategic planning.
Mr. Johal is a director and clinical subject matter expert for SAJO Consulting LLC. He is also the CEO of Next Level Medication Management INC, a Canadian based company dedicated to healthcare innovation and sustainability.
Mr. Johal is a graduate from the Leslie Dan Faculty of Pharmacy at the University of Toronto. He holds a Board Certification in Psychiatric Pharmacy, awarded by the Board of Pharmacy Specialties in the United States. He is a clinical instructor at UBC’s Faculty of Pharmaceutical Sciences and has worked as lead clinical pharmacist for a number of outreach programs including the Integrated Medication Management Program and the Coast Mental Health Medication Program.
“Ajit brings to Blake Insomnia Therapeutics a valued combination of pharmaceutical expertise with academic experience,” said Birger Jan Olsen, President and CEO of Blake Insomnia Therapeutics. “His experience in psychiatric pharmacotherapy brings tremendous value to the development of Blake Insomnia’s portfolio of novel and innovative pharmaceutical products.” Both Mr. Sarwal and Mr. Ajit will start working on the board as soon as the Company has obtained Director’s and Officer’s Insurance.
Sajo Consulting LLC
Sajo designs solutions and strategies in getting products to market faster and smarter. Their research, scientific, regulatory and operational team puts best practice standards to work while building innovative solutions for constantly evolving industries.
Blake Insomnia Therapeutics Inc.
Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™.
Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.
Contact Birger Jan Olsen CEO Blake Insomnia Therapeutics Inc. 1 (888) 612-2905 [email protected]
